This review covers the development and clinical efficacy of various GLP-1-based therapeutics, exploring the challenges and future directions in obesity management
When you work with Dr
Its emotional connection score moves from 2.8 to 3.8, and among ZOA-aware GLP-1 users, 44% say they will definitely purchase it, versus 27% of ZOA-aware Adults
Since November, 2023, empagliflozin is now indicated in people aged 10 years as a monotherapy if metformin is not tolerated (and diet and exercise alone do not provide adequate glycaemic control), or in combination with other glucose-lowering medicines (under specialist supervision) if glycaemic control remains poor
The standard escalation protocol starts at 0.25 mg/week and progresses through 0.5, 1.0, 1.7, and 2.4 mg/week maintenance doses
Always interpret results with your healthcare provider